Jasmina Brooks
May 17, 2023 — Biosense Webster, Inc., a global leader in cardiac arrhythmiatreatment and part of Johnson & Johnson MedTech, announced that Jasmina (Jass) Brooks as President, Biosense Webster. In this role, Brooks will have accountability for setting Biosense Webster’s global strategy, and advancing its innovation agenda, to position the organization for continued growth. Brooks succeeds Michael Bodner, Ph.D. who has assumed the role of Global Head of Heart Recovery for Johnson & Johnson MedTech.
Brooks comes to the role with nearly 25 years of experience in the cardiovascular field, primarily focused on electrophysiology. She is a nine-year veteran of Biosense Webster, and her background is ideally suited to assume leadership of the organization and oversee its next phase of innovation and growth.
Most recently, Brooks was Vice President, Global Strategic Marketing, Biosense Webster. In this role, she worked with cross-functional and international teams to set the strategy and shape the company product pipeline to drive growth, market share, and profitability. Brooks joined Biosense Webster in 2014 and held positions of increasing scope and responsibility in the Global Strategic Marketing Organization. Prior to joining Johnson & Johnson, Brooks spent 15 years at GE Healthcare, where she held various roles in commercial marketing, global strategic marketing, product development and engineering in the US and EMEA. Brooks holds a Bachelor of Science in Biomedical Engineering from Louisiana Tech University.
“Jass Brooks is a well-respected, collaborative leader with a deep knowledge of the electrophysiology space, a track record of successfully driving growth and market leadership, as well as a deep commitment to developing talent and fostering a culture of collaboration and inclusivity,” said Celine Martin, Company Group Chairman, Cardiovascular & Specialty Solutions Group, Johnson & Johnson. “Jass has dedicated her career to championing excellence in patient outcomes and solving unmet medical needs, and she will continue to harness this passion in leading Biosense Webster as the company advances innovation solutions to help people with Afib live the lives they want.”
“It is an honor to lead Biosense Webster, with its proud legacy and unmatched capabilities in cardiac catheter ablation,” said Brooks. “I look forward to continuing to partner closely with the electrophysiology community to elevate standards of care in AFib.”
For more information: www.biosensewebster.com
July 18, 2024 
